Digital therapeutics improve Parkinson’s control, study shows

By Published On: 26 November 2024
Digital therapeutics improve Parkinson’s control, study shows

A study has revealed that Parkinson’s disease patients using a telemonitoring device saw improved or stable symptom manifestation.

The study investigated the progression of Parkinson’s symptoms over two years for 17 patients who were previously evaluated using traditional methods.

Physicians integrated PDMonitor, a telemonitoring device developed by PD Neurotechnology, for each patient and used it to assess symptoms in their daily lives which informed decisions about their care.

The results of the study provide real-world evidence that remote continuous monitoring can have a positive impact on PD symptom control:

  • The time patients in the study spent in the “Off” state – when the effects of medication used to control symptoms had worn off and symptoms returned or worsened – reduced from 36.2 per cent to 20.3 per cent over the period in which subjects used the monitoring device.
  • Almost half (44.4 per cent) of patients reported an improvement in their condition attributable to telemonitoring, while another 37 per cent indicated their condition was unchanged. These findings show a positive impact on symptom control, as motor function is expected to worsen significantly over time for patients on a typical treatment regime.
  • There was a notable increase in the percentage of patients reporting that they were “satisfied” with the effectiveness of their medication after using telemonitoring, improving from 26.9 per cent to 38.5 per cent over the two years. The percentage of patients saying they were “very satisfied” increased from 7.7 per cent to 23.1 per cent.

Nikos Moschos, Managing Director of PD Neurotechnology, commented: “We are very excited about the results of this study. It is clear that digital therapeutics, which involves continuous monitoring of patients in their daily lives and more informed medication adjustments based on real-world data, paves the way for a paradigm shift in Parkinson’s Disease.

“The increased patient satisfaction identified in this study is directly associated with the personalised treatment made possible by remote continuous monitoring.”

Parkinson's vaccine show positive safety results in clinical trial
Tavapadon meets primary endpoint in Phase 3 trial for Parkinson's